KRAS and cholangiocarcinoma: Although effective targeted therapies for KRAS mutations in CCA have historically been scarce, recent innovations in drug development have begun to overcome the challenge of KRAS being considered “undruggable.” The phase II trial (NCT03785249) investigated the KRAS G12C-specific inhibitor adagrasib (MRTX849) in 64 patients with advanced solid tumors harboring this mutation, including 8 with CCA.